Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus DURICEF.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic